Platinum/etoposide regimens carry an intermediate risk of febrile neutropenia in extensive-stage small cell lung cancer ...

Mogamulizumab (Poteligeo) was associated with durable real-world treatment outcomes in patients with mycosis fungoides (MF) ...

The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end ...

Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...

Elevar Therapeutics and Hengrui Pharma have resubmitted applications to the FDA seeking approval of rivoceranib plus ...

Texas Oncology’s virtual care navigation pilot supported 740 patients on oral oncolytics across 11 community sites, offering ...

Pollack, MD, and participants discussed 2 investigational agents for recurrent diffuse tenosynovial giant cell tumor and how ...

The FDA has allowed the launch of a phase 2 study of MT027, an allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Paula Rodriguez-Otero, MD, discusses how T-cell–engaging therapies are aiming to meaningfully impact or negate the disease course of high-risk smoldering myeloma. High-risk smoldering multiple myeloma ...

Alicia Morgans, MD, explains how the ARACOG trial showed higher cognitive decline with enzalutamide vs darolutamide in ...

Explore why some patients with multiple myeloma miss stem cell transplant, spotlighting age, race and socioeconomic barriers, ...